For research use only
| Cat No. | ABC-TC0427 |
| Product Type | Human Bladder Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bladder |
| Disease | Bladder Cancer |
| Product Code | HT1376; HT 1376; HT 1376.T |
The line does not contain detectable virus particles, herpesvirus antigens or retrovirus antigens. The cells will grow in soft agar.
HT-1376 is a human urothelial carcinoma cell line originally established from a grade 3 transitional carcinoma of the urinary bladder in a 58-year-old Caucasian female patient. It displays an epithelial-like morphology and grows as adherent monolayers in standard culture conditions. HT-1376 cell line harbors characteristic genomic alterations such as TERT promoter C228T, TP53 p.Pro250Leu, and RB1 p.Gln702Ter, which reflect its malignant background and relevance to urothelial carcinoma progression. HT-1376 cells exhibit structural microvilli and tonofibrils indicative of epithelial differentiation and grow in soft agar, demonstrating anchorage-independent growth and tumorigenicity in immunocompromised rodents. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | HT1376; HT 1376; HT 1376.T |
| Species | Human |
| Cat.No | ABC-TC0427 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bladder |
| Disease | Bladder Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Bladder Cancer Cell Lines |
HT-1376 cells are used as an in vitro human bladder carcinoma model to investigate tumor cell proliferation, tumorigenic mechanisms, and urothelial cancer drug responses. Their genomic alterations and robust growth support studies of signal transduction pathways, DNA damage responses, and preclinical evaluation of anticancer therapeutics relevant to translational bladder cancer research.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
